Back to first-pass browser

First-pass extracted concept

Alzheimer's disease

Candidate: concept label3 source documents5 linked claims
Jump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

AD

Evidence Snippets

Nanobodies (single-domain antibodies, VHHs) have emerged as versatile tools for evaluating and treating Alzheimer's disease (AD).
Evidence 1Source 1DOIPubMedprovenance
Research hotspots include transcranial magnetic stimulation, noninvasive brain stimulation, Parkinson's disease, and Alzheimer's disease.
Evidence 2Source 2DOIPubMedprovenance
The amyloid hypothesis of Alzheimer's disease at 25 years
Evidence 3Source 3DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1research focussupports2025Source 2DOIPubMed

Transcranial ultrasound stimulation is currently used primarily in neurological diseases, particularly in studies of Parkinson's disease and Alzheimer's disease.

Claim 2research hotspotsupports2025Source 2DOIPubMed

Research hotspots in the analyzed literature include transcranial magnetic stimulation, noninvasive brain stimulation, Parkinson's disease, and Alzheimer's disease.

Claim 3translational statussupports2025Source 1DOIPubMed

Nanobody applications in Alzheimer's disease remain preclinical and direct clinical evidence in patients is lacking.

Quoted textsource-backed
However, all nanobody applications in AD are discussed strictly as preclinical therapeutic potential rather than established clinical therapies, and direct clinical evidence in patients with AD is still lacking.
Claim 4disease timing modelsupports2016Source 3DOIPubMed

The review presents biomarker evidence that amyloid abnormalities precede clinical symptoms by decades in dominantly inherited Alzheimer's disease.

Quoted textsource-backed
directly supports the review’s claim that amyloid abnormalities precede symptoms by decades
Claim 5review scope summarysupports2016Source 3DOIPubMed

This review synthesizes evidence supporting the amyloid hypothesis of Alzheimer's disease from genetics, biomarker timing, and amyloid-beta handling mechanisms.